Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) kicked off on Friday, down -15.99% from the previous trading day, before settling in for the closing price of $0.22. Over the past 52 weeks, ADAP has traded in a range of $0.04-$0.91.
A company in the Healthcare sector has jumped its sales by 26.53% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -60.00%. With a float of $255.41 million, this company’s outstanding shares have now reached $265.05 million.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adaptimmune Therapeutics Plc ADR is 3.64%, while institutional ownership is 27.57%. The most recent insider transaction that took place on Sep 02 ’25, was worth 950. In this transaction Chief Financial Officer of this company sold 96,000 shares at a rate of $0.01, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Chief Financial Officer proposed sale 16,000 for $0.06, making the entire transaction worth $942.
Adaptimmune Therapeutics Plc ADR (ADAP) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.01 earnings per share (EPS), higher than consensus estimate (set at -0.18) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -60.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.87% during the next five years compared to 26.53% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Take a look at Adaptimmune Therapeutics Plc ADR’s (ADAP) current performance indicators. Last quarter, stock had a quick ratio of 1.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.19 in one year’s time.
